Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), the Administrators notified the registrant of an increase in the notional allocation of Ordinary share ADRs on July 29, 2010. The transaction occurred at a price of $35.16 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: July 29, 2010.
- Transaction Price: $35.16 per ADR.
- Involved Parties: Dr M M Slaoui (7 units), Mrs C E Bruck Slaoui (2 units), Mr E J Gray (22 units), Mr W C Louv (14 units), Dr D Pulman (27 units), and Ms D Connelly (1 unit).
- Plan Details: The transaction relates to the US Retirement Savings Plan, where investments are notionally held in GSK Ordinary share ADRs.